Table 1 Demographic and clinical characteristics of statin users and non-users
| Â | Before PS matching | After PS matching | ||||
|---|---|---|---|---|---|---|
|  | Statin users (n = 964) | Non-users (n = 7376) | P-value* | Statin users (n = 618) | Non-users (n = 1585) | P-value** |
Demographic | Â | Â | Â | Â | Â | Â |
Mean age (SD), years | 68.3 (10.6) | 66.6 (12.9) | <0.001 | 67.9 (10.9) | 67.4 (11.9) | 0.91 |
Male sex, n(%) | 539 (55.9) | 4433 (60.1) | 0.013 | 345 (55.8) | 891 (56.2) | 0.99 |
Mean BMI (SD), kg/m2 | 24.1 (3.3) | 23.6 (3.7) | <0.001 | 23.9 (3.3) | 23.8 (3.4) | 0.99 |
Pre-stroke mRS, n(%) | Â | Â | <0.001 | Â | Â | 0.68 |
0 | 834 (86.5) | 6909 (93.7) | Â | 552 (89.3) | 1458 (92.0) | Â |
1 | 130 (13.5) | 467 (6.3) | Â | 66 (10.7) | 127 (8.0) | Â |
Risk factors, n(%) | Â | Â | Â | Â | Â | Â |
Hypertension | 800 (83.0) | 4765 (64.6) | <0.001 | 482 (78.0) | 1200 (75.7) | 0.89 |
DM | 458 (47.5) | 2250 (30.5) | <0.001 | 269 (43.5) | 643 (40.6) | 0.90 |
Hyperlipidemia | 807 (83.7) | 1771 (24.0) | <0.001 | 461 (74.6) | 1007 (63.5) | 0.74 |
Smoking | 344 (35.7) | 3068 (41.6) | <0.001 | 219 (35.4) | 575 (36.3) | 0.92 |
Atrial fibrillation | 210 (21.8) | 1307 (17.7) | 0.002 | 133 (21.5) | 305 (19.2) | 0.76 |
History of stroke | 345 (35.8) | 1153 (15.6) | <0.001 | 186 (30.1) | 400 (25.2) | 0.80 |
History of CAD | 147 (15.3) | 272 (3.7) | <0.001 | 58 (9.4) | 135 (8.5) | 0.59 |
Lab, mean(SD) | Â | Â | Â | Â | Â | Â |
SBP, mmHg | 148.5 (26.9) | 149.2 (27.4) | 0.46 | 148.6 (26.1) | 149.4 (28.0) | 0.89 |
DBP, mmHg | 84.2 (15.0) | 87.0 (15.6) | <0.001 | 85.5 (15.0) | 85.8 (16.3) | 0.98 |
Hemoglobin | 13.4 (1.9) | 13.8 (1.9) | <0.001 | 13.6 (1.9) | 13.6 (1.9) | 0.56 |
Admission glucose, mg/dL | 124.5 (51.1) | 123.4 (52.4) | 0.38 | 126.7 (51.9) | 126.6 (52.8) | 0.81 |
Total cholesterol, mg/dL | 164.0 (42.0) | 185.3 (40.8) | <0.001 | 173.8 (43.3) | 180.1 (42.6) | 0.67 |
LDL cholesterol, mg/dL | 93.6 (33.3) | 113.4 (35.4) | <0.001 | 101.6 (34.8) | 106.8 (37.3) | 0.67 |
Stroke characteristics | Â | Â | Â | Â | Â | Â |
Median onset to arrival time (IQR), hours | 7.0 (2.5 - 19.5) | 7.7 (3.0 - 20.0) | 0.040 | 7.1 (2.5 - 19.9) | 7.4 (2.8 - 19.8) | 0.99 |
Stroke subtype, n(%) | Â | Â | Â | Â | Â | 0.98 |
Large artery atherosclerosis | 361 (37.5) | 2678 (36.3) | <0.001 | 226 (36.6) | 597 (37.7) | Â |
Small vessel occlusion | 168 (17.4) | 1790 (24.3) | <0.001 | 116 (18.8) | 334 (21.1) | Â |
Cardioembolism | 234 (24.3) | 1477 (20.0) | <0.001 | 153 (24.8) | 352 (22.2) | Â |
Others | 201 (20.9) | 1431 (19.4) | <0.001 | 123 (19.9) | 302 (19.1) | Â |
SYSO | 409 (42.4) | 3011 (40.8) | 0.34 | 257 (41.6) | 651 (41.1) | 0.81 |
Pre-stroke medication, n(%) | Â | Â | Â | Â | Â | Â |
Antiplatelet | 671 (69.6) | 1479 (20.1) | <0.001 | 351 (56.8) | 722 (45.6) | 0.92 |
Anticoagulant | 85 (8.8) | 251 (3.4) | <0.001 | 45 (7.3) | 99 (6.2) | 0.93 |
ARB or ACEI | 435 (45.1) | 1221 (16.6) | <0.001 | 225 (36.4) | 484 (30.5) | 0.60 |
Beta-blocker | 207 (21.5) | 485 (6.6) | <0.001 | 104 (16.8) | 221 (13.9) | 0.93 |
Diuretics | 179 (18.6) | 554 (7.5) | <0.001 | 93 (15.0) | 209 (13.2) | 0.86 |
Calcium channel blocker | 327 (33.9) | 1124 (15.2) | <0.001 | 170 (27.5) | 404 (25.5) | 0.85 |